Molecular structure of NSC-207895, CAS Number: 58131-57-0
NSC-207895 (CAS 58131-57-0)
Alternate Names:
2,1,3-Benzoxadiazole, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium
Application:
NSC-207895 is an anticancer agent and p53 activator. This compound decreases the expression of MDMX but also induced the expression of MDM2.
CAS Number:
58131-57-0
Purity:
≥98%
Molecular Weight:
279.25
Molecular Formula:
C11H13N5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nsc-207895 is a derivative of nitrobenzofuroxan. Nsc-207895 also upregulated the expression of p53 in MCF-7 cells that led to increased expression of proapoptotic genes including PUMA, BAX, as well as PIG3. Notably, Nsc-207895, also called a small-molecule p53 activator, gives rise to MCF-7 cells to experience apoptosis and decrease the viability of cancer cells along with nutlin-3a, which dissociated the MDM2-p53 complex. Nsc-207895 is an electrophilic compound that has antitumor and mutagenic activities. Nsc-207895 may lead to the damage of DNA that inhibits the growth of tumors. Nsc-207895 is an inhibitor of MDMX.
NSC-207895 (CAS 58131-57-0) References
- A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. | Wang, H., et al. 2011. Mol Cancer Ther. 10: 69-79. PMID: 21075910
- Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. | Kapitzky, L., et al. 2010. Mol Syst Biol. 6: 451. PMID: 21179023
- Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. | Bogachek, MV., et al. 2016. Stem Cell Reports. 7: 1140-1151. PMID: 27916539
- Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells. | Chopra, H., et al. 2018. Oncotarget. 9: 6270-6281. PMID: 29464071
- MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. | Woodfield, SE., et al. 2021. Sci Rep. 11: 2967. PMID: 33536467
- Rewiring of Lactate-Interleukin-1β Autoregulatory Loop with Clock-Bmal1: a Feed-Forward Circuit in Glioma. | Gowda, P., et al. 2021. Mol Cell Biol. 41: e0044920. PMID: 34124933
- Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort. | Taghvaei, S., et al. 2021. Front Pharmacol. 12: 700454. PMID: 34276383
- Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. | Vuaroqueaux, V., et al. 2021. NPJ Precis Oncol. 5: 96. PMID: 34711913
- The N6-Methylandenosine-Related Gene BIRC5 as a Prognostic Biomarker Correlated With Cell Migration and Immune Cell Infiltrates in Low Grade Glioma. | Jiang, X., et al. 2022. Front Mol Biosci. 9: 773662. PMID: 35309512
- Clustering analysis revealed the autophagy classification and potential autophagy regulators' sensitivity of pancreatic cancer based on multi-omics data. | Chen, Y., et al. 2023. Cancer Med. 12: 733-746. PMID: 35684936
- Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer. | Sung, JY. and Cheong, JH. 2022. Cancers (Basel). 14: PMID: 35804967
- Comprehensive Analysis of the Aberrance and Functional Significance of Ferroptosis in Gastric Cancer. | Xiao, J., et al. 2022. Front Pharmacol. 13: 919490. PMID: 35903347
- Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma. | Ju, L., et al. 2022. PeerJ. 10: e14506. PMID: 36570012
- Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. | Liu, T., et al. 2023. Biomolecules. 13: PMID: 36830695
- Mechanical overloading-induced miR-325-3p reduction promoted chondrocyte senescence and exacerbated facet joint degeneration. | Zhao, J., et al. 2023. Arthritis Res Ther. 25: 54. PMID: 37016437
Inhibitor of:
karyopherin α3, MDMX, Mnt, MYH13, Skp1, smoothelin, and Sox-9.Activator of:
53BP1, Dicer, LI-cadherin, MDM2, NF-1C, p53, and SMYD3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NSC-207895, 5 mg | sc-364550 | 5 mg | $347.00 | |||
NSC-207895, 10 mg | sc-364550A | 10 mg | $653.00 |